Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTOR Activating Mutation”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT02201212
What this trial is testing

Everolimus for Cancer With TSC1 or TSC2 Mutation

Who this might be right for
TSC1TSC2Tuberous Sclerosis Complex+1 more
Dana-Farber Cancer Institute 30
Not applicableApproved For MarketingNCT03817515
What this trial is testing

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Who this might be right for
PEComa, MalignantTSC1TSC2+1 more
Aadi Bioscience, Inc.
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Testing effectiveness (Phase 2)Study completedNCT03190174
What this trial is testing

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Who this might be right for
Ewing SarcomaPEComaEpithelioid Sarcoma+11 more
Sarcoma Oncology Research Center, LLC 34